David McIntosh: The Evolving Safety Framework for Plasma-Derived Therapies
David McIntosh, Founder and Chair of United Plasma Action, shared Plasma Protein Therapeutics Association’s post on LinkedIn:
“This interesting piece of work will be of significant interest to anyone working in, or interested in, this field of life-saving medicines.
A footnote to add is that what is being described is the 80 percent of current World supplies of plasma that are achieved via Voluntary Reasonably Compensated Donation (VRCD).
Plasma obtained via so-called ‘Unpaid Donation’ almost certainly generates similar results, but as there is so much less of it in the World, relevant data is more scarce.
What is certainly clear, from the vast body of evidence gathered throughout the years of this Century, is that VRCD plasma collection is as safe as, if not safer than, unpaid donor plasma.
As safe – and much more of it – is surely a winning formula!”
Plasma Protein Therapeutics Association (PPTA) shared a post on LinkedIn about a recent article by Halide Tuna et al, published in Annals of Blood, adding:
“A new peer-reviewed publication authored by PPTA’s Halide Tuna and Dr. Toby Simon explores how plasma-derived medicinal products have achieved today’s strong safety profile.
The publication in Annals of Blood highlights the evolution of the ‘safety tripod’ — donor screening, testing, and pathogen reduction — and its role in ensuring the continued safety of plasma-derived therapies.
The conclusion is clear: strong, science-driven systems continue to protect patients today, while ongoing surveillance, periodic evaluation of methods, and technological innovations are essential for future preparedness.”
Title: Plasma-derived medicinal products: a narrative review of the multi-layered approach to ensuring pathogen safety
Authors: Halide Tuna, Toby Simon
Other posts featuring David McIntosh on Hemostasis Today.
-
Jun 26, 2026, 18:28Daniel Pereira Monteiro: Why Is Beta Thalassaemia Major so Severe?
-
Jun 26, 2026, 18:27Pradip Pawar: Cell and Gene Therapy – Transforming Medicine in the 21st Century
-
Jun 26, 2026, 18:26Aviva Schwartz: How Can We Better Protect Patients After an Ischemic Stroke?
-
Jun 26, 2026, 18:25Does Reversing Factor Xa Inhibitors Really Carry as Much Thrombotic Risk as We Think? – RPTH Journal
-
Jun 26, 2026, 18:25Akshat Jain: Novel Therapies in Childhood Blood and Cancer Disorders
-
Jun 26, 2026, 16:57Abdul Muqtadir Abbasi: Anticoagulation in DVT Patients With Hidden Varices Requires Extreme Caution
-
Jun 26, 2026, 16:42Anesa Mulabecirovic: Why Von Willebrand Disease Takes Years to Diagnose in Women
-
Jun 26, 2026, 16:32Kaitlin Lichty: A New Identity Reflecting a Shared Legacy of Bleeding Disorders
-
Jun 26, 2026, 16:07Toong Youttananukorn: The WFH Registry Driving Better Care and Advocacy